When a patient on MASH pharmacotherapy meets NIT-based progression criteria (e.g., ≥30% rise in VCTE liver stiffness or ≥0.5 increase in ELF), what minimum evaluation do you require to rule out confounders (inflammation, congestion, alcohol exposure, weight cycling) before declaring true progression and changing/discontinuing therapy?